title: Successful treatment of bcr/abl-positive acute mixed lineage leukemia by unmanipulated bone marrow transplantation from an HLA-haploidentical (3-antigen-mismatched) cousin.
abstract: We describe a patient with bcr/abl-positive acute mixed lineage leukemia who successfully underwent transplantation in primary induction failure, using unmanipulated bone marrow from a human leukocyte antigen (HLA)-haploidentical cousin. The tumor burden was successfully reduced by the administration of imatinib mesylate (STI571) before transplantation. As graft-versus-host disease (GVHD) prophylaxis, a combination of tacrolimus and a short course of methotrexate, methylprednisolone, and mycophenolate mofetil was used. Hematopoietic reconstitution was rapid, and acute GVHD was limited to the skin (grade I). The patient is still in complete remission past day +400. This successful case suggests that HLA-haploidentical transplantation using unmanipulated marrow from a distantly related relative can be considered for patients in urgent situations who do not have HLA-identical donors.
authors.affiliation: Department of Molecular Medicine, Osaka University Graduate School of Medicine, Suita city, Osaka, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Ikegame
authors.forename: C
authors.initials: C
authors.lastname: Mukouchi
authors.forename: A
authors.initials: A
authors.lastname: Kunitomi
authors.forename: Y
authors.initials: Y
authors.lastname: Konaka
authors.forename: M
authors.initials: M
authors.lastname: Kawakami
authors.forename: S
authors.initials: S
authors.lastname: Nishida
authors.forename: Y
authors.initials: Y
authors.lastname: Taniguchi
authors.forename: T
authors.initials: T
authors.lastname: Fujioka
authors.forename: T
authors.initials: T
authors.lastname: Masuda
authors.forename: M
authors.initials: M
authors.lastname: Murakami
authors.forename: N
authors.initials: N
authors.lastname: Hosen
authors.forename: E H
authors.initials: EH
authors.lastname: Kim
authors.forename: A
authors.initials: A
authors.lastname: Tsuboi
authors.forename: Y
authors.initials: Y
authors.lastname: Oji
authors.forename: Y
authors.initials: Y
authors.lastname: Oka
authors.forename: H
authors.initials: H
authors.lastname: Sugiyama
authors.forename: I
authors.initials: I
authors.lastname: Kawase
authors.forename: H
authors.initials: H
authors.lastname: Ogawa
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D005190:Family; D005260:Female; D016313:Genes, abl; D006086:Graft vs Host Disease / Q000517:prevention & control; D006680:HLA Antigens / Q000235:genetics; D006239:Haplotypes; D006801:Humans; D000068877:Imatinib Mesylate; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D015456:Leukemia, Biphenotypic, Acute / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D008727:Methotrexate / Q000008:administration & dosage; D008775:Methylprednisolone / Q000008:administration & dosage; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives*; D010375:Pedigree; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D016559:Tacrolimus / Q000008:administration & dosage; D014019:Tissue Donors; D014184:Transplantation, Homologous
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D006680:HLA Antigens; D007166:Immunosuppressive Agents; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D009173:Mycophenolic Acid; D016559:Tacrolimus; D008775:Methylprednisolone; D008727:Methotrexate